甲福明真的可以降低前列腺癌风险吗:最新的综合基因组全方位分析
1Chengdu New Radiomedicine Technology Co. Ltd, Chengdu, Sichuan, China.
Diabetology & metabolic syndrome
|July 12, 2024
概括
这项研究没有发现任何证据表明甲福明可以降低前列腺癌风险. 需要进一步的研究来证实甲胺的抗癌作用.
科学领域:
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲福明使用与前列腺癌 (PCa) 风险之间的关联仍在争论中.
- 之前的研究还没有明确确地确定甲胺在PCa预防中的作用.
研究的目的:
- 调查甲福明使用与前列腺癌 (PCa) 风险之间的因果关系.
- 进行全面的全基因组分析,以澄清甲胺对PCa的潜在保护作用.
主要方法:
- 在以前的研究中,利用了用于甲福明的验证仪器变量,重点关注五个潜在的目标 (AMPK,GCG,GDF15,MCI,MG3).
- 使用来自大型全基因组关联研究 (GWAS) 的数据进行了门德尔随机化 (MR) 分析 - PRACTICAL和FinnGen队列.
- 应用了七种MR方法并进行了严格的灵敏度分析,以确保发现的有效性.
主要成果:
- 确定了32个与甲胺使用相关的显著单核酸多态 (SNPs).
- 大多数目标显示无意义的结果;然而,AMPK目标建议在FinnGen队列中与PCa风险有积极的关联 (OR:6.09,P=0.038).
- 综合所有目标的总体分析不支持在任何一个队列中使用甲福明和降低PCa风险之间的因果关系.
结论:
- 这项研究不支持甲胺在降低前列腺癌风险方面的保护作用.
- 这些发现需要重新评估梅特福明的广泛治疗效果.
- 建议通过正在进行的III期试验进行进一步的研究,以评估甲福林的抗新生体潜力.
相关概念视频
01:11Genome-wide Association Studies-GWAS
13.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187